ANI Pharma (ANIP) Misses Q4 EPS by 8c, Offers FY Guidance

ANI Pharma (NASDAQ: ANIP) reported Q4 EPS of $0.52, $0.08 worse than the analyst estimate of $0.60. Revenue for the quarter came in at $18.04 million versus the consensus estimate of $18.13 million.

GUIDANCE:

ANI Pharma sees FY2016 revenue of $105-120 million, versus the consensus of $91.8 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
• NXP Semiconductors names Mike Lucarelli as new investor relations head
• BMO Capital on FedEx (FDX): 'Guidance Appears Consistent With Our Forecasts'